Atara Biotherapeutics Q3 revenue beats estimates

Overview

• Atara Q3 2025 revenue beats analyst expectations despite a significant year-over-year decline

• Company reported a net loss of $4.3 mln for Q3 2025, down from $21.9 mln in 2024

• Atara reduced workforce by 29% to focus on strategic priorities

Outlook

• Atara expects $40 mln milestone payment upon tab-cel BLA approval

• Company projects 2025 operating expenses to decrease by at least 60%

• Atara explores strategic alternatives to maximize shareholder value

Result Drivers

• TAB-CEL TRANSFER - Completion of tab-cel activities transfer to Pierre Fabre Laboratories, including BLA sponsorship and costs, expected to reduce operating expenses

• WORKFORCE REDUCTION - Atara reduced workforce by 29% to focus on strategic priorities, retaining essential employees

• CASH FLOW IMPACT - Decrease in cash receipts from Pierre Fabre after 2024 milestones contributed to increased net cash used in operating activities

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $16.50, about 23.9% above its November 11 closing price of $12.56

Press Release: ID:nBw68xF6Ca

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)